iShares Biotechnology ETF
Tracks NYSE Biotechnology Index
The four numbers that price an ETF.
What the ETF actually owns.
From the most recent SEC N-PORT filing. The top-10 weight tells you how concentrated the fund is — broad-market trackers run 25-30%, single-theme funds often 50-70%.
| # | Holding | Weight | Value (USD) | Asset class |
|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 7.75% | $629 M | EC |
| 2 | Amgen, Inc. | 7.51% | $610 M | EC |
| 3 | Vertex Pharmaceuticals, Inc. | 7.44% | $605 M | EC |
| 4 | Regeneron Pharmaceuticals, Inc. | 7.21% | $586 M | EC |
| 5 | Alnylam Pharmaceuticals, Inc. | 3.99% | $324 M | EC |
| 6 | Insmed, Inc. | 3.20% | $260 M | EC |
| 7 | Argenx SE | 3.07% | $250 M | EC |
| 8 | Biogen, Inc. | 2.46% | $200 M | EC |
| 9 | Natera, Inc. | 2.41% | $196 M | EC |
| 10 | United Therapeutics Corp. | 2.30% | $187 M | EC |
| 11 | BeOne Medicines Ltd. | 1.93% | $157 M | EC |
| 12 | Incyte Corp. | 1.70% | $138 M | EC |
| 13 | Moderna, Inc. | 1.68% | $137 M | EC |
| 14 | Illumina, Inc. | 1.68% | $136 M | EC |
| 15 | Revolution Medicines, Inc. | 1.54% | $125 M | EC |
| 16 | Roivant Sciences Ltd. | 1.24% | $101 M | EC |
| 17 | Neurocrine Biosciences, Inc. | 1.18% | $96 M | EC |
| 18 | Genmab A/S | 1.17% | $95 M | EC |
| 19 | Bridgebio Pharma, Inc. | 1.13% | $92 M | EC |
| 20 | Ionis Pharmaceuticals, Inc. | 1.11% | $91 M | EC |
| 21 | Medpace Holdings, Inc. | 1.00% | $82 M | EC |
| 22 | Madrigal Pharmaceuticals, Inc. | 1.00% | $81 M | EC |
| 23 | Exelixis, Inc. | 0.99% | $80 M | EC |
| 24 | BioMarin Pharmaceutical, Inc. | 0.98% | $80 M | EC |
| 25 | Ascendis Pharma A/S | 0.96% | $78 M | EC |
What we measure and what we leave out.
Data sources: SEC EDGAR N-PORT filings (holdings + filing-date timestamp); issuer fact sheets for expense ratio + AUM + inception; Yahoo Finance for daily NAV.
Expense ratio is the single biggest forward predictor of long-horizon performance. A 0.03% expense ratio compounds to a fundamentally different outcome than a 0.95% expense ratio over 25 years — even if the underlying index is identical.
Concentration risk lives in the top-10 weight. For broad-market trackers (VOO, VTI, SPY) the top-10 sits around 28-32%. For thematic funds — semiconductors, AI, cannabis — top-10 often crosses 60%. A "sector tilt" with 60% in 10 names is closer to active stock-picking than passive index exposure.
LRS + tax for Indian investors: US-listed ETFs are securities for Indian-tax purposes — held > 24 months = LTCG @ 12.5%, ≤ 24 months = slab-rate STCG. Distributions are dividends taxed at slab rates (US withholds 25%, creditable via DTAA). LRS USD 250,000 / FY cap applies to each remittance.
India-listed alternative: for S&P 500 / NASDAQ-100 exposure without LRS friction, see India-listed ETFs at /etfs/ (Motilal Oswal, Mirae, Nippon, etc. variants). Higher TER but no LRS hassle and INR-settled.
What this page does not model: tracking error vs underlying index, premium/discount to NAV, bid-ask spread on-exchange, currency-hedged variants (e.g. JPST-hedged), securities lending revenue (which subsidises some expense ratios).
ETF NAVs, tracking error and AUM are computed from AMFI disclosures. ETFs are subject to market risk and tracking-error risk. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.